Additional Phase 2 Data Supports Further Development of Tanox's Novel HIV Therapy

Company Presents In-Depth Analysis of TNX-355 Phase 2 Results at 45th ICAAC Meeting 


WASHINGTON, Dec. 17  /PRNewswire-FirstCall/ -- Tanox, Inc. (NASDAQ:TNOX) today presented further analysis of a Phase 2 study of its novel HIV antibody, TNX-355, in a late-breaking submission at the American Society for Microbiology's Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).  The company, which recently released favorable Week 24 viral-reduction results for the drug candidate, had an abstract at the meeting.  The presentation provided details on several endpoints of the study.

In addition to meeting the primary endpoint of mean change in viral load from baseline with statistical significance, TNX-355, combined with an optimized background regimen (OBR), demonstrated considerable virologic benefit compared to OBR alone as measured by average area under the curve minus baseline (AAUCMB).  The AAUCMB for the 15 milligram-per-kilogram (mg/kg) dose arm was a 0.97 log(10) reduction (p=0.001) in viral load by Week 24, while the AAUCMB for the 10 mg/kg dose arm was a 1.20 log(10) reduction (p